JP2022519375A5 - - Google Patents
Info
- Publication number
- JP2022519375A5 JP2022519375A5 JP2021546211A JP2021546211A JP2022519375A5 JP 2022519375 A5 JP2022519375 A5 JP 2022519375A5 JP 2021546211 A JP2021546211 A JP 2021546211A JP 2021546211 A JP2021546211 A JP 2021546211A JP 2022519375 A5 JP2022519375 A5 JP 2022519375A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- amino
- composition according
- cancer
- azaspiro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962804708P | 2019-02-12 | 2019-02-12 | |
| US62/804,708 | 2019-02-12 | ||
| PCT/IB2020/051031 WO2020165734A1 (en) | 2019-02-12 | 2020-02-10 | Pharmaceutical combination comprising tno155 and ribociclib |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022519375A JP2022519375A (ja) | 2022-03-23 |
| JP2022519375A5 true JP2022519375A5 (https=) | 2023-02-17 |
| JP7493521B2 JP7493521B2 (ja) | 2024-05-31 |
Family
ID=69724013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021546211A Active JP7493521B2 (ja) | 2019-02-12 | 2020-02-10 | Ｔｎｏ１５５及びリボシクリブを含む医薬組合せ |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12343344B2 (https=) |
| EP (1) | EP3923941B1 (https=) |
| JP (1) | JP7493521B2 (https=) |
| KR (1) | KR20210126653A (https=) |
| CN (1) | CN113382731A (https=) |
| AU (3) | AU2020222296B2 (https=) |
| BR (1) | BR112021015632A2 (https=) |
| CA (1) | CA3127286A1 (https=) |
| CL (1) | CL2021002099A1 (https=) |
| ES (1) | ES3063733T3 (https=) |
| IL (1) | IL284835B2 (https=) |
| MX (1) | MX2021009563A (https=) |
| TW (1) | TWI831916B (https=) |
| WO (1) | WO2020165734A1 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112867718B (zh) | 2018-09-29 | 2025-03-04 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物的制造 |
| IL305106B2 (en) | 2018-09-29 | 2025-08-01 | Novartis Ag | Process of manufacture of a compound for inhibiting the activity of shp2 |
| EP3860717A1 (en) | 2018-10-03 | 2021-08-11 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| MX2021009562A (es) * | 2019-02-12 | 2021-09-08 | Novartis Ag | Combinacion farmaceutica que comprende tno155 y un inhibidor de pd-1. |
| IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
| US12441737B2 (en) | 2020-07-08 | 2025-10-14 | Novartis Ag | Manufacture of compounds and compositions for inhibiting the activity of SHP2 |
| US20250195521A1 (en) | 2020-09-03 | 2025-06-19 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| CA3194067A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Ras inhibitors |
| CN117177752A (zh) * | 2021-05-05 | 2023-12-05 | 诺华股份有限公司 | 用于治疗mpnst的化合物和组合物 |
| JP2024516450A (ja) | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | 共有結合性ｒａｓ阻害剤及びその使用 |
| JP2024516997A (ja) * | 2021-05-05 | 2024-04-18 | フヤバイオ インターナショナル，エルエルシー | Ｓｈｐ２阻害剤単独療法およびその使用 |
| TW202309052A (zh) | 2021-05-05 | 2023-03-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| KR20240017811A (ko) | 2021-05-05 | 2024-02-08 | 레볼루션 메디슨즈, 인크. | 암의 치료를 위한 ras 억제제 |
| US20240293422A1 (en) * | 2021-06-24 | 2024-09-05 | Erasca, Inc. | Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| TW202342040A (zh) | 2022-02-21 | 2023-11-01 | 瑞士商諾華公司 | 藥物配製物 |
| JP2025510572A (ja) | 2022-03-08 | 2025-04-15 | レボリューション メディシンズ インコーポレイテッド | 免疫不応性肺癌を治療するための方法 |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| EP4626890A1 (en) | 2022-12-01 | 2025-10-08 | KRKA, d.d., Novo mesto | Ribociclib salts and formulations thereof |
| KR20240097396A (ko) | 2022-12-20 | 2024-06-27 | 재단법인대구경북과학기술원 | 리보시클립을 유효성분으로 포함하는 신경염증 또는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| CR20250420A (es) | 2023-04-07 | 2025-11-20 | Revolution Medicines Inc | Inhibidores macrocíclicos de ras |
| AR132338A1 (es) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | Inhibidores de ras |
| CN121100123A (zh) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Ras抑制剂的结晶形式 |
| CN121464140A (zh) | 2023-04-14 | 2026-02-03 | 锐新医药公司 | Ras抑制剂的结晶形式、含有其的组合物及其使用方法 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2522346T3 (es) | 2008-08-22 | 2014-11-14 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de CDK |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| CA3048340A1 (en) | 2017-01-10 | 2018-07-19 | Novartis Ag | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
| CA3074690A1 (en) * | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| AU2019403048B2 (en) | 2018-12-17 | 2025-01-23 | Lunella Biotech, Inc. | Triple combination therapies for targeting mitochondria and killing cancer stem cells |
| AU2019402099B2 (en) | 2018-12-17 | 2025-01-23 | Lunella Biotech, Inc. | Triple combination therapies for anti-aging |
| MX2021009562A (es) | 2019-02-12 | 2021-09-08 | Novartis Ag | Combinacion farmaceutica que comprende tno155 y un inhibidor de pd-1. |
| US20220152026A1 (en) | 2019-02-12 | 2022-05-19 | Novartis Ag | Pharmaceutical combination comprising tno155 and a krasg12c inhibitor |
-
2020
- 2020-02-10 EP EP20707827.0A patent/EP3923941B1/en active Active
- 2020-02-10 IL IL284835A patent/IL284835B2/en unknown
- 2020-02-10 TW TW109104042A patent/TWI831916B/zh active
- 2020-02-10 CA CA3127286A patent/CA3127286A1/en active Pending
- 2020-02-10 ES ES20707827T patent/ES3063733T3/es active Active
- 2020-02-10 WO PCT/IB2020/051031 patent/WO2020165734A1/en not_active Ceased
- 2020-02-10 KR KR1020217028654A patent/KR20210126653A/ko not_active Ceased
- 2020-02-10 JP JP2021546211A patent/JP7493521B2/ja active Active
- 2020-02-10 US US17/430,219 patent/US12343344B2/en active Active
- 2020-02-10 BR BR112021015632-1A patent/BR112021015632A2/pt unknown
- 2020-02-10 CN CN202080012520.8A patent/CN113382731A/zh active Pending
- 2020-02-10 MX MX2021009563A patent/MX2021009563A/es unknown
- 2020-02-10 AU AU2020222296A patent/AU2020222296B2/en active Active
-
2021
- 2021-08-10 CL CL2021002099A patent/CL2021002099A1/es unknown
-
2023
- 2023-06-15 AU AU2023203751A patent/AU2023203751A1/en not_active Abandoned
-
2025
- 2025-05-23 AU AU2025203816A patent/AU2025203816A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022519375A5 (https=) | ||
| JP2022519385A5 (https=) | ||
| JP2022520079A5 (https=) | ||
| JP5579715B2 (ja) | ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ | |
| JP2024526145A5 (https=) | ||
| CN102065866B (zh) | 包括甲胺蝶呤及二氢乳清酸脱氢酶抑制剂的组合 | |
| JP2019516733A5 (https=) | ||
| CN102292108A (zh) | 包括甲胺喋呤以及二氢乳清酸脱氢酶抑制剂的组合 | |
| JP2023175694A5 (https=) | ||
| JP2025020117A5 (https=) | ||
| JP2019526595A5 (https=) | ||
| JP2016523858A (ja) | がんを治療するためのｂｔｋ阻害剤とフルオロウラシルとの併用 | |
| JP2024527109A5 (https=) | ||
| CN104039148A (zh) | 组合als疗法 | |
| JP2023524789A5 (https=) | ||
| JP2025013684A (ja) | 重度腎機能障害を有する癌患者に対する治療方法 | |
| JP2021503448A5 (https=) | ||
| JP2005513167A (ja) | エポシロン誘導体と代謝拮抗剤からなる組合せ | |
| Nathwani et al. | Toxicities associated with metformin/ritonavir combination treatment in relapsed/refractory multiple myeloma | |
| JP2023531090A5 (https=) | ||
| JP2024517788A5 (https=) | ||
| RU2021126526A (ru) | Фармацевтическая комбинация, содержащая tno155 и рибоциклиб | |
| JPWO2022260132A5 (https=) | ||
| JP2024518426A5 (https=) | ||
| CN105263499A (zh) | 用于癌症治疗的ro5503781、卡培他滨和奥沙利铂的组合 |